# V1 Empirics Check — x-ai/grok-4.1-fast (Variant A)

**Model:** x-ai/grok-4.1-fast
**Variant:** A
**Date:** 2026-03-24T21:54:08.570662

---

### 1. Idea Fidelity
The paper deviates substantially from the original idea manifest. The manifest proposes a causal IV strategy using quasi-random ALJ assignment within hearing offices to instrument for county-level SSDI/SSI enrollment, linked to DEA ARCOS opioid shipments (2006-2014), CMS Medicare Part D prescribing, and CDC overdose mortality. Key elements include: (i) constructing leave-one-out ALJ leniency at the hearing-office-by-year level; (ii) geographic crosswalks from ~165 hearing offices to counties; (iii) first-stage F-stat >>100 from Maestas et al. (2013); (iv) exclusion via office and year FEs; (v) mechanism test via SSDI's 24-month Medicare lag vs. immediate SSI Medicaid; and (vi) primary outcomes on *prescribing intensity* (shipments per capita, prescriptions per enrollee), not just mortality.

None of these are implemented. Instead, the paper uses a state-year panel (2015-2022) of ACS disability *prevalence* (not SSDI/SSI enrollment) on CDC overdose *mortality* rates, with simple state-year FEs and a "difference-in-drugs" placebo. No ALJ data, no IV, no county/hearing-office variation, wrong time period (post-fentanyl, missing ARCOS overlap), no prescribing outcomes, and no timing test. The research question shifts from "causal effect of disability receipt on opioid prescribing" to "is the disability-mortality correlation causal via insurance?" This is not a faithful pursuit but a complete pivot to a correlational debunking exercise.

### 2. Summary
This paper examines whether disability insurance causally contributes to opioid mortality via insurance-mediated prescribing, using state-year panel data (2015-2022) on ACS disability prevalence and CDC overdose deaths by drug type. Employing state and year fixed effects, it finds the cross-sectional positive correlation reverses to negative within states, and a "difference-in-drugs" placebo shows similar negative associations for prescription and illicit drugs (e.g., fentanyl, cocaine). It concludes the "pill pipeline" is a confound driven by common economic factors like despair, not causation, especially in the fentanyl era.

### 3. Essential Points
The paper has fundamental flaws in identification, execution, and alignment with its (revised) question, warranting outright rejection for AER: Insights. Three critical issues must be addressed, but the cumulative deviations suggest major rework is infeasible within the format:

1. **No credible causal identification**: The manifest promised (and AER: Insights demands) a rigorous quasi-experimental design like the ALJ-IV, with established first-stage strength (F>>100) and clear exclusion (leniency affects outcomes only via enrollment). The paper delivers OLS on aggregate prevalence with state-year FEs, which identifies only reduced-form correlations within states over time. This cannot support causal claims about disability *receipt* on mortality (prevalence conflates incidence, exits, and migration). The "difference-in-drugs" placebo is clever for mechanisms but assumes parallel trends across drugs absent disability—violated if economic shocks (e.g., unemployment) differentially affect drug preferences. Without instruments or finer variation, confounders like state policy changes (PDMPs, naloxone access) or fentanyl supply shocks bias β^d uniformly.

2. **Empirical approach mismatches research question**: The question tests an *insurance-prescribing channel*, but outcomes are *mortality*, not prescribing (no ARCOS, CMS Part D, or shipments). Mortality reflects use + lethality + treatment access; even if causal, it conflates prescribing with diversion/illicit supply. The 2015-2022 fentanyl era obscures prescription effects (synthetic opioids dominate, per summary stats: 16.2 vs. 5.0 per 100k). No timing test exploits SSDI's 24-month lag vs. SSI immediacy, despite manifest emphasis. Pre-2019 split (Table 3) shows weakly positive effects (127, p>0.10), but imprecision and small N=102 preclude inference.

3. **Data and specification inadequacies undermine results**: ACS 5-year disability prevalence is smoothed (acknowledged limitation), attenuating dynamics; lagged specs (Table 3 col. 2) remain negative/null. State-level aggregation loses power (N=261, wide CIs: e.g., -546 (366)), with only 41 states (excludes high-mortality WV/KY systematically?). Clustering at state ignores serial correlation; no state trends despite threats. Cross-sectional reversal is unsurprising (high-disability states like Appalachia have persistent high mortality), but within-state negative β implies implausible reverse causality (disability *falls* with mortality?).

Revise to implement the ALJ-IV on prescribing (2006-2014), or reframe as descriptive; current form fails AER: Insights causal standards.

### 4. Suggestions
While the core flaws necessitate rejection, the paper has strengths worth salvaging: crisp writing, intuitive placebo framing, policy relevance, and awareness of limitations (e.g., ecological fallacy). Refocus on the manifest's IV for a stronger AER: Insights submission. Concrete recommendations:

#### Data and Implementation
- **Implement ALJ-IV faithfully**: Download SSA ALJ Disposition Data (data.gov, FY2006-2014 for ARCOS overlap). Compute leave-one-out leniency per ALJ (Maestas et al. 2013 code available). Aggregate to hearing-office-year (N~1,500), crosswalk to counties via SSA office ZIPs + Census cartographic boundaries (free). First stage: AwardRate_{ho,t} = π Leniency_{ho,t} + FEs + ε; report F-stat per office. Link to ARCOS county shipments (Mendeley pre-aggregated: doi:10.17632/dwfgxrh7tn.7) for log(pills/capita), CMS Part D opioids/enrollee. Reduced form: Pills_{c,t} = γ Leniency_{ho(c),t} + controls + county/ho/year FEs.
- **Add mortality as secondary outcome**: CDC WONDER county deaths (2006-2020); test lags (0-36 months) for SSDI vs. SSI (SSA data distinguishes).
- **Controls/threats**: County unemployment/income (BLS/ACS); % manufacturing (QCEW). Event studies around ALJ rotations. Balance tests: leniency orthogonal to applicant diagnoses (SSA data has condition codes).

#### Specifications and Robustness
- **Timing/mechanism tests**: Interact leniency with SSDI/SSI shares (SSA aggregates). Expect pills +2y for SSDI, immediate for SSI. Placebo: non-opioid prescriptions (CMS).
- **Clustering/power**: Cluster at hearing office (165 clusters); report Anderson-Rubin CI for weak IV. Power calc: with σ(leniency)=0.15, ~10k county-years, detect 5-10% prescribing effects.
- **Era robustness**: Split 2006-2010 (prescription wave) vs. 2011-2014 (heroin shift); fentanyl post-2013 minimal in ARCOS era.

#### Framing and Extensions
- **Title/abstract**: Revert to "Pill Pipeline" causal claim; emphasize novelty (first IV on prescribing). Quantify: if τ=0.1 pills/enrollee, scale to epidemic costs (13M beneficiaries).
- **Placebo integration**: Use *your* difference-in-drugs on IV-reduced form (prescribed vs. illicit mortality)—stronger than OLS.
- **Heterogeneity**: By ALJ office rurality (% rural counties), baseline prescribing, or applicant conditions (musculoskeletal vs. mental, SSA data).
- **Policy**: Simulate tightening ALJ standards (e.g., -10pp allowances) reduces pills by X, deaths by Y. Link to Gelber et al. (2024) mortality IV.
- **Extensions**: Individual-level: SSA-CMS linked claims (RDC access) for beneficiary opioids post-award. County supply: physicians/PCP ratio (HRSA).

#### Tables/Figures
- Add: Fig. 1 binned scatter (leniency vs. pills, residuals post-FEs); Fig. 2 event study (pills t=0 to t=+36 by SSDI/SSI).
- Table 1: Add first stage (F=??), ITT on enrollment/pills/mortality.
- Appendix: Raw correlations (replicate Lazo/Cossio 28-46% R2); pre-trends.

This pivots to a novel, causal contribution (70% feasibility per manifest). Total rework ~2-3 months; resubmit post-replication files (GitHub ideal). Engaging lit review—keep Case/Krueger hooks.
